focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Where is the info that Abingdon supply Medco device.
We also remain confident in delivering significant value from opportunities within the COVID-19 testing space. Our positive dialogues with the third parties introduced to us by the Department of Health and Social Care (DHSC) are advancing and we are optimistic that these will conclude successfully and positively impact on our H2 performance.
I can still see it
Just checked. Still showing. Scroll down to the bottom.
https://www.medusa19.com/en/
Found it
Nice find. Can you post the link
Reading between the lines, this may indicate that phase 1a dosing is going well. Why bother offering or accepting if the trial was not showing signs of success?
https://www.zerohedge.com/covid-19/ends-debate-israeli-study-shows-natural-immunity-13x-more-effective-vaccines-stopping
Even more reason for antibody testing
Looks like USA hospital
"As a COVID-19 test is a medical device used for diagnosis, the UK government proposes using the Medicines and Medical Devices Act to establish a regulatory regime which will require manufacturers of COVID-19 tests to independently validate the performance of their tests in order for these to be placed on the UK market.
This will place a legal duty for manufacturers to go through the validation process before supplying COVID-19 tests. It would be a criminal offence for manufacturers, vendors or distributors to sell unvalidated tests.
The UK government is also considering introducing a ‘manner of sale’ statutory instrument (SI) which will require a notification before a purchase is made from a manufacturer or distributor. This will be an effective tool in raising awareness among people purchasing COVID-19 detection tests"
Scardey:
Received the following from Lord Hunt:
Further to your email, I'm trying to track down when this legislation is likely to reach the Lords.
Any idea?
He removed the post after someone pointed out the same letter had been sent to a number of MP's , Lords and mainstream media outlets. Looked like he was trying to pass it off as his own!
I sent this e-mail to Lord Hunt and got this response
Hi
Thanks for your email.
I will look into this
Best wishes
Philip
The Rt Hon Lord Hunt of Kings Heath PC OBE
Text: 07774 358 407
Tel: 020 7219 2030
Email:huntp@parliament.uk
Twitter: @LordPhilofBrum
Follow our activities on social media:
Twitter: @LabourLordsUK
Facebook: www.facebook.com/LabourLordsUK
Blog: www.labourlords.org.uk
UK Parliament Disclaimer: this e-mail is confidential to the intended recipient. If you have received it in error, please notify the sender and delete it from your system. Any unauthorised use, disclosure, or copying is not permitted. This e-mail has been checked for viruses, but no liability is accepted for any damage caused by any virus transmitted by this e-mail. This e-mail address is not secure, is not encrypted and should not be used for sensitive data.
Omega Diagnostics Group PLC Regulatory progress for VISITECT(R) COVID-19 test
Source: UK Regulatory (RNS & others)
TIDMODX
RNS Number : 0850B
Omega Diagnostics Group PLC
08 June 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Regulatory progress for VISITECT(R) COVID-19 Antigen test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, provides the following update on VISITECT(R) COVID-19 Antigen test regulatory approvals.
Regulatory approvals
Omega announces that it has begun the process of engagement with its European Notified Body seeking CE marking of the VISITECT(R) COVID-19 Antigen test, a rapid point-of-care diagnostic test for the detection of active COVID-19 infections as a self-test. The Company is agreeing the protocols required for utilisation studies and will update shareholders as this process progresses. The test is already CE marked for professional-use and the Company is targeting approval by the end of July to allow the test to be sold in Europe for home-use as well. As the global market for Antigen testing develops the Company believes self-test approval will be a key product differentiator, as has already been seen in the UK.
The Company also announces that its technology partner, Mologic Ltd ("Mologic") has successfully completed the necessary performance studies required for regulatory approval in the US and is now in the final stages of preparing a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its rapid point-of-care COVID-19 antigen test, for use under both the Omega's VISITECT(R) brand and Global Access Diagnostics brand.
Colin King, CEO of Omega, commented:
"I am pleased with the progress we are making to gain regulatory approval, both for our VISITECT self-test product and for US professional use. Both routes offer potentially significant opportunities as we believe we have a high quality product with global appeal."
Contacts:
Omega Diagnostics Group PLC www.omegadiagnostics.com Colin King, Chief Executive via Walbrook PR Kieron Harbinson, Group Finance Director finnCap Ltd Tel: 020 7220 0500 Geoff Nash/Edward Whiley (Corporate Finance) Alice Lane (ECM) Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as
Note the RNS from Omega. Still waiting on government to select sovereign test......
Account started 1 June. Absolute tvat...
However, there is a growing consensus that a viral load as measured by PCR of Ct<27 should be considered as infectious. The clinical data for Avacta's AffiDX(R) SARS-CoV-2 antigen lateral flow test demonstrated 100% sensitivity for identifying infectious individuals in this range.
However, there is a growing consensus that a viral load as measured by PCR of Ct<27 should be considered as infectious. The clinical data for Avacta's AffiDX(R) SARS-CoV-2 antigen lateral flow test demonstrated 100% sensitivity for identifying infectious individuals in this range.